GSK shares fell after a Food and Drug Administration advisory committee voted against approval of the company's Blenrep drug, a setback for its bid to reintroduce the blood-cancer treatment in the U.S ...

GSK specialty medicines grew YoY in Q1 2025, and it is now the main profit engine, offsetting the weakness in their vaccine segment. See why the stock is a Buy.

Sitamraju Sree Ramakrishna, manager projects, at GlaxoSmithKline Consumer Healthcare’s (GSKCH) Rajahmundry factory, raised a ...

AI inference attacks drain enterprise budgets, derail regulatory compliance and destroy new AI deployment ROI.

Hindustan Unilever naming Priya Nair as MD and chief executive officer receives a big thumbs up from investors as stocks gain despite market slump, but there are many challenges to address for the FMC ...

An update from Harte-Hanks ( (HHS)) is now available. On June 24, 2025, Harte Hanks, Inc. extended its $25 million secured revolving line of credit with Texas Capital Bank, now maturing in June 2028.

Investors in GSK plc (Symbol: GSK) saw new options begin trading today, for the August 8th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the GSK options chain ...

In May, biotech iTeos Therapeutics decided to close down after being abandoned by GSK over the disappointing mid-stage ...

GSK (GSK) faces an investigation from U.S. Senator Maggie Hassan over its decision to discontinue Flovent HFA asthma inhaler last year. Read more here.

The Sensex dropped 502 points on Friday to close at 81,758, while the Nifty slipped 143 points to end below the 25,000 mark ...

Senator Maggie Hassan is investigating GSK's discontinuation of Flovent HFA, citing increased hospitalizations, higher drug costs, and lost Medicaid rebates.